文献速递MDS 与骨髓增殖性肿瘤

突变增强的国际预后系统用于原发性血小板增多症和真性红细胞增多症

Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.
PubMed 文献 · Br J Haematol · 2020-01-16

研究纳入906例分子学注释的ET和PV患者,多变量分析确定剪接体突变影响总生存和无骨髓纤维化生存,TP53突变预测ET白血病转化。基于风险点分配开发的三层突变增强国际预后系统在双队列中验证,性能优于传统评分系统。

要点

  • 剪接体突变(ET中SF3B1、SRSF2;PV中SRSF2)与不良总生存相关
  • ET中U2AF1、SF3B1突变影响无骨髓纤维化生存,TP53突变预测白血病转化
  • 基于突变、年龄、性别、白细胞计数和血栓史的MIPSS预后分层优于传统评分

核心结论

  • 剪接体突变增强ET和PV的生存预测并识别纤维化进展风险患者。
  • TP53突变预测ET的白血病转化。

研究设计与样本

  • 研究纳入906例分子学注释患者(Mayo Clinic 416例;意大利佛罗伦萨大学490例),包括502例ET和404例PV。

主要发现

  • ET中不良突变见于51例(10%),PV中8例(2%)。
  • 基于HR的风险点分配开发三层突变增强国际预后系统(MIPSS),在双队列中验证且性能优于传统评分系统。

临床怎么用

  • 对ET和PV患者可整合剪接体突变和TP53突变信息进行预后分层。
  • MIPSS可用于识别高危患者,指导临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Survival prediction in essential thrombocythaemia (ET) and polycythaemia vera (PV) is currently based on clinically-derived variables; we examined the possibility of integrating genetic information for predicting survival. To this end, 906 molecularly-annotated patients (416 Mayo Clinic; 490 University of Florence, Italy), including 502 ET and 404 PV, were recruited. Multivariable analysis identified spliceosome mutations to adversely affect overall (SF3B1, SRSF2 in ET and SRSF2 in PV) and myelofibrosis-free (U2AF1, SF3B1 in ET) survival; TP53 mutations predicted leukaemic transformation in ET; "adverse" mutations occurred in 51 (10%) ET and 8 (2%) PV patients. We confirmed the independent survival effect of adverse mutations [hazard ratio (HR) 2·4, 95% CI 1·6-3·5], age >60 years (6·6, 4·6-9·7), male sex (1·8, 1·3-2·4) and leukocytosis ≥11 × 109 /l (1·6, 1·1-2·2), in ET, and adverse mutations (7·8, 3·1-17·0), age >67 years (5·4, 3·6-8·1), leukocytosis ≥15 × 109 /l (2·8, 1·8-4·2) and thrombosis history (2·0, 1·4-2·9), in PV. HR-based risk point allocation allowed development of three-tiered mutation-enhanced international prognostic systems (MIPSS) which were validated in both cohorts and performance was shown to be superior to conventional scoring systems. Spliceosome mutations enhance survival prediction in ET and PV and identify patients at risk for fibrotic progression. TP53 mutations predict leukaemic transformation in ET.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Tefferi A, Guglielmelli P, Lasho TL, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020. PMID: 31945802. doi:10.1111/bjh.16380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。